Ambrx Biopharma Inc
NYSE:AMAM
Income Statement
Earnings Waterfall
Ambrx Biopharma Inc
Revenue
|
5.7m
USD
|
Operating Expenses
|
-94m
USD
|
Operating Income
|
-88.3m
USD
|
Other Expenses
|
5.7m
USD
|
Net Income
|
-82.6m
USD
|
Income Statement
Ambrx Biopharma Inc
Jun-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|
Revenue | ||||||
Revenue |
5
N/A
|
7
+41%
|
7
+0%
|
6
-24%
|
6
+1%
|
|
Operating Income | ||||||
Operating Expenses |
(84)
|
(74)
|
(90)
|
(68)
|
(94)
|
|
Selling, General & Administrative |
(19)
|
(43)
|
(31)
|
(27)
|
(37)
|
|
Research & Development |
(64)
|
(31)
|
(59)
|
(41)
|
(57)
|
|
Operating Income |
(78)
N/A
|
(67)
+15%
|
(83)
-24%
|
(63)
+24%
|
(88)
-41%
|
|
Pre-Tax Income | ||||||
Interest Income Expense |
(1)
|
0
|
1
|
3
|
6
|
|
Non-Reccuring Items |
(10)
|
(10)
|
(10)
|
0
|
0
|
|
Total Other Income |
(0)
|
(0)
|
0
|
0
|
0
|
|
Pre-Tax Income |
(89)
N/A
|
(76)
+14%
|
(91)
-20%
|
(59)
+35%
|
(82)
-39%
|
|
Net Income | ||||||
Tax Provision |
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
|
Income from Continuing Operations |
(91)
|
(78)
|
(93)
|
(60)
|
(83)
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
(91)
N/A
|
(78)
+14%
|
(93)
-20%
|
(60)
+36%
|
(83)
-39%
|
|
EPS (Diluted) |
-0.32
N/A
|
-0.29
+9%
|
-0.29
N/A
|
-0.15
+48%
|
-1.32
-780%
|